Neuralstem in the News
“After the Ice Bucket” - Neuralstem NSI-566/ALS Interview with Richard Garr
Neuralstem's President and CEO, Richard Garr, sets out the company’s progress towards its goal of creating a neural stem cell therapy that will make ALS a manageable chronic disease and give patients a normal lifespan and good quality of life in this nearly six-minute TV segment, one of four on the future of ALS research produced by BioCentury in partnership with WUSA9, the CBS affiliate in Washington, D.C. Mr. Garr gives a thorough overview of NSI-566/ALS, including the neural stem cells; specially designed surgical devices used for the world’s first intraspinal injections; “rescue, nurture and integrate” treatment benefits, and Phase I final cohort three-year results from peer-reviewed, published data. NSI-566/ALS Phase II trials concluded final surgeries in July 2014.
Spinal gap: Neuralstem goes into chronic injuries phase I, first ever cleared by FDA
Neuralstem’s President and CEO, Richard Garr, is interviewed in this cover story reporting on the promise of Neuralstem’s NSI-566/chronic spinal cord injury (cSCI) Phase I trial, now underway at the University of California, San Diego School of Medicine. This trial, like Neuralstem’s ongoing NSI-566/ALS trials, represents the first FDA-approved stem cell trial for the indication. While both trials use the same cells and similar procedure, Mr. Garr explains that in addition to neurotrophic factors, in spinal cord injury patients the NSI-566 mechanism of action includes rebuilding neural circuitry for structural repair, “literally bridging the gap… trying to rebuild the circuitry in the gap so that the signal can come through, down the spinal cord.”
Opinion: This tiny biotech company takes the real ice bucket challenge
Financial writer, Michael Brush, looks ahead of the $100 million-plus raised in the ALSA Ice Bucket Challenge to the potential of biotech treatments for ALS. Neuralstem’s recently completed NSI-566/ALS Phase II and upcoming Phase II/III trials are the focus of the opinion piece. Principal Investigator, Eva Feldman, MD, PhD, notes that she hopes “the ice bucket money goes to fast-tracking new therapies,” and Neuralstem’s President and CEO, Richard Garr, projects that, “We could be as close as two years away from commercialization.”
Research making ALS less of a mystery
CBS’s chief medical correspondent features Neuralstem NSI-566/ALS patient and trial on CBS national news story as a promising ALS treatment.
NSI-566/ALS Patient Ted Harada Interview
Paul Knoepfler, PhD, of the University of California, Davis, interviewed NSI-566/ALS Phase I patient, Ted Harada, in a two-part blog produced by the Knoepfler Lab at UC Davis School of Medicine.
- UCSD Looking For Spinal Cord Injury Patients To Test Stem Cell Treatment
- Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries
- UM researcher Eva Feldman takes on ALS, Alzheimer’s and ‘The Daily Show’
- Researchers Fret as Social Media Lift Veil on Drug Trials
- Neurogenic Drug Improves Depression in Small Trial
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.